WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that further analyses from the Company’s Phase 2b investigational trial of FOLOTYN® (pralatrexate injection) compared to erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC) will be presented as a late-breaking oral presentation at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This meeting will be held December 9-11 in Chicago, Illinois and is co-sponsored by the American Society of Clinical Oncology (ASCO), American Society for Radiation Oncology (ASTRO), International Association for the Study of Lung Cancer (IASLC), and the University of Chicago.
